Uchechukwu Ikeaba

Featured in: Favicon

Articles

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction | Cardiology | JAMA Cardiology | JAMA Network

Nov 18, 2024 | jamanetwork.com | Mohammad Jawad |Kansas City |John A. Spertus |Uchechukwu Ikeaba

Key PointsQuestion How has the adoption rate and variation in use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) changed for US patients with heart failure and left ventricular ejection fraction greater than 40% since publication of clinical trial evidence of benefit in 2021?
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry | Cardiology | JAMA Cardiology | JAMA Network

Oct 31, 2024 | jamanetwork.com | Jacob Pierce |Muthiah Vaduganathan |Gregg C. Fonarow |Uchechukwu Ikeaba

Key PointsQuestion What is the prevalence and variability of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use among patients with heart failure with reduced ejection fraction (HFrEF) in the US? Findings In this cohort study including 49 399 patients hospitalized for HFrEF in the Get With The Guidelines–Heart Failure registry, 1 in 5 patients were discharged with prescriptions for SGLT2i therapy; rates were similarly low in patients with comorbid type 2 diabetes and chronic kidney disease.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.